How big is Beam Therapeutics, Inc.?

As of Jun 18, Beam Therapeutics, Inc. has a market capitalization of $1.68 billion, with net sales of $63.58 million and a net profit of -$387.34 million over the last four quarters. The company reported shareholder's funds of $733.54 million and total assets of $1.10 billion as of Dec 24.

Market Cap: As of Jun 18, Beam Therapeutics, Inc. has a market capitalization of 1,676.29 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Beam Therapeutics reported net sales of 63.58 million and a net profit of -387.34 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 733.54 million and total assets of 1,103.82 million.

What does Beam Therapeutics, Inc. do?

Beam Therapeutics, Inc. is a biotechnology company specializing in precision genetic medicines through base editing technology, with a market cap of approximately $1.68 billion. As of March 2025, it reported net sales of $7 million and a net loss of $109 million.

Overview:<BR>Beam Therapeutics, Inc. is a biotechnology company focused on developing precision genetic medicines using its base editing technology, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -109 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,676.29 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.07 <BR>Return on Equity: -34.16% <BR>Price to Book: 1.49<BR><BR>Contact Details:<BR>Address: 26 Landsdowne St, CAMBRIDGE MA: 02139-4216 <BR>Tel: 1 857 3278775 <BR>Website: https://beamtx.com/

Should I buy, sell or hold Beam Therapeutics, Inc.?

Who are in the management team of Beam Therapeutics, Inc.?

As of March 2022, the management team of Beam Therapeutics, Inc. is led by CEO John Evans, with a board that includes Independent Directors Kathleen Walsh, Kristina Burow, Graham Cooper, Mark Fishman, and Carole Ho.

As of March 2022, the management team of Beam Therapeutics, Inc. includes Mr. John Evans, who serves as the Chief Executive Officer and Director. Additionally, the board consists of Ms. Kathleen Walsh, Ms. Kristina Burow, Mr. Graham Cooper, Dr. Mark Fishman, and Dr. Carole Ho, all of whom hold the designation of Independent Director.

Is Beam Therapeutics, Inc. overvalued or undervalued?

As of February 28, 2022, Beam Therapeutics, Inc. is considered risky and overvalued with key financial metrics indicating unsustainable valuation despite a recent short-term gain, as it has a Price to Book Value of 1.66, an EV to Sales ratio of 10.40, and a troubling 3-year return of -55.27% compared to the S&P 500's 70.41%.

As of 28 February 2022, the valuation grade for Beam Therapeutics, Inc. moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 1.66, an EV to Sales ratio of 10.40, and a ROE of -34.16%. In comparison to peers, Blueprint Medicines Corp. has a significantly higher EV to EBITDA of -53.3160, while Arrowhead Pharmaceuticals, Inc. shows an EV to EBITDA of -40.5602, indicating that Beam's valuation is not justified relative to its industry peers.<BR><BR>Despite a strong 1-week return of 16.47% compared to the S&P 500's 1.05%, the longer-term performance reveals a concerning trend, with a 3-year return of -55.27% versus the S&P 500's 70.41%. This suggests that while there may be short-term gains, the overall valuation remains unsustainable in the context of its financial performance.

Is Beam Therapeutics, Inc. technically bullish or bearish?

As of October 31, 2025, Beam Therapeutics, Inc. shows a mildly bullish technical trend, supported by bullish daily moving averages and weekly MACD, but tempered by a bearish weekly RSI and underperformance compared to the S&P 500.

As of 31 October 2025, the technical trend for Beam Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the weekly RSI is bearish, suggesting some weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames. Dow Theory shows a mildly bearish weekly outlook but a mildly bullish monthly perspective. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -8.31% compared to the S&P 500's 16.30%, and a three-year return of -48.33% versus 76.66% for the index. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals from the RSI and Dow Theory.